Effective Date: 02/01/2013
Last P&T Approval/Version: 10/27/2021
Next Review Due By: 11/2022
Policy Number: C10424-A

Stelara (ustekinumab)

PRODUCTS AFFECTED

Stelara (ustekinumab)

COVERAGE POLICY

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.
This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines

Documentation Requirements:
Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational, or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive

DIAGNOSIS:
moderate to severe plaque psoriasis (Ps), active psoriatic arthritis (PsA), moderately to severely active Crohn’s disease (CD), ulcerative colitis.

REQUIRED MEDICAL INFORMATION:
This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label information along with state and federal requirements, benefit being administered and formulary preferencing. Coverage will be determined on a case-by-case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review

FOR ALL INDICATIONS:

1. (a) Prescriber attests member has had a negative TB screening or TB test result within the last 12 months for initial and continuation of therapy requests
   OR
   (b) For members who have a positive test for latent TB, provider documents member has completed a treatment course (a negative chest x-ray is also required every 12 months) OR that

member has been cleared by an infectious disease specialist to begin treatment
AND

2. Prescriber attests member has been evaluated and screened for the presence of hepatitis B virus (HBV) prior to initiating treatment
AND
3. Member is not on concurrent treatment or will be used in combination with other TNF- inhibitor, biologic response modifier or other biologic DMARDs, Janus kinase Inhibitors, or Phosphodiesterase 4 inhibitor (i.e., apremilast, tofacitinib, baricitinib) as verified by prescriber attestation, member medication fill history, or submitted documentation
AND
4. Prescriber attests member does not have an active infection, including clinically important localized infections
AND
5. IF THIS IS A NON-FORMULARY/NON-PREFERRED PRODUCT: Documentation of trial/failure of or intolerance to amajority (not more than 3) of the preferred formulary/PDL alternatives for the given diagnosis. If yes, please submit documentation including medication(s) tried, dates of trial(s) and reason for treatment failure(s)

A. PSORIATIC ARTHRITIS (PsA):
1. Documentation of active psoriatic arthritis
AND
2. Documentation of prescriber baseline disease activity evaluation and goals for treatment to be used to evaluate efficacy of therapy
AND
3. (a)Documented treatment failure with or FDA labeled contraindication to a minimum 3-month trial ofONE of the following: Leflunomide, Methotrexate, Sulfasalazine, Cyclosporine
OR
(b) Documentation member has severe psoriatic arthritis [erosive disease, elevated markers of inflammation, long term damage that interferes with function, highly active disease that causes amajor impairment in quality of life, active PsA at many sites including dactylitis, enthesitis, function-limiting PsA at a few sites or rapidly progressive disease]
OR
(c) Documentation member has severe psoriasis [PASI ≥12, BSA of >5-10%, significant involvement in specific areas (e.g., face, hands or feet, nails, intertriginous areas, scalp), impairment of physical or mental functioning with lower amount of surface area of skin involved]

B. CHRONIC PLAQUE PSORIASIS:
1. Documented diagnosis of moderate to severe psoriasis (BSA 3%-10%-moderate, >10%-severe) OR ≤10% body surface area with plaque psoriasis that involves sensitive areas of the body or areas that would significantly impact daily function (ex. face, neck, hands, feet, genitals)AND
2. (a) Documentation of treatment failure with or a clinical contraindication to TWO of the following systemic therapies for ≥ 3 months: Methotrexate (oral or IM at a minimum dose of15 mg/week), cyclosporine, acitretin, azathioprine, hydroxyurea, leflunomide, mycophenolate mofetil, sulfasalazine, or tacrolimus
OR
(b) Documentation of treatment failure to Phototherapy for ≥3 months with either psoralens with ultraviolet A (PUVA) or ultraviolet B (UVB) radiation (provider to submit documentation of duration of treatment, dates of treatment, and number of sessions; contraindications include type 1 or type 2 skin, history of photosensitivity, treatment of facial lesions, presence of premalignant lesions, historyof melanoma or squamous cell carcinoma, or physical inability to stand for the required exposure time)
AND

3. Documentation of prescriber baseline disease activity evaluation and goals for treatment to be used to evaluate efficacy of therapy at renewal

C. MODERATE TO SEVERE ACTIVE CROHN'S DISEASE:
1. Documentation of a diagnosis of currently ACTIVE moderate to severely active Crohn's Disease AND
2. (a) Member has had a trial (>3 months) and inadequate response to ONE immunomodulator (e.g., azathioprine, 6-mercaptopurine, methotrexate) up to maximally indicated doses unless contraindicated or significant adverse reactions are experienced
   OR
   (b) Prescriber provides documented medical justification that supports the inability to use immunomodulators
   i. Inability to induce short-term symptomatic remission with a 3-month trial of systemic glucocorticoids
   ii. High-risk factors for intestinal complications may include: Initial extensive ileal, ileocolonic, or proximal GI involvement, Initial extensive perianal/severe rectal disease, Fistulizing disease (e.g., perianal, enterocutaneous, and rectovaginal fistulas), Deep ulcerations, Penetrating, stricturing or stenosis disease and/or phenotype, Intestinal obstruction, or abscess
   iii. High risk factors for postoperative recurrence may include: Less than 10 years duration between time of diagnosis and surgery, Disease location in the ileum and colon, Perianal fistula, Prior history of surgical resection, Use of corticosteroids prior to surgery
   AND
3. Documentation of prescriber baseline disease activity evaluation and goals for treatment to be used to evaluate efficacy of therapy at renewal
   AND
4. FOR INITIAL SC THERAPY: The Member has received a single induction dose with Stelara IV within 2 months of initiating therapy with Stelara SC

D. ULCERATIVE COLITIS:
1. Documentation of ulcerative colitis diagnosis with evidence of moderate to severe diseaseactivity AND
2. (a) Member has had a 2-month trial of one systemic agent (e.g., 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone, methylprednisolone) or was intolerant to one of these agents for ulcerative colitis or will continue to take concurrently.
   NOTE: A previous trial of a biologic (e.g., an adalimumab product [e.g., Humira], Simponi SC [golimumabSCinjection], or Entyvio [vedolizumab IV infusion] also counts as a trial of one systemic agent for UC)
   OR
   b) The Member has pouchitis AND has tried therapy with an antibiotic (e.g., metronidazole, ciprofloxacin), probiotic, corticosteroid enema [for example, Cortenema® {hydrocortisone enema, generics}], or Rowasa® (mesalamine) enema
   AND
3. Documentation of prescriber baseline disease activity evaluation and goals for treatment to be used to evaluate efficacy of therapy at renewal
   AND
4. FOR INITIAL SC THERAPY: The Member has received a single induction dose with Stelara IV within 2 months of initiating therapy with Stelara SC

CONTINUATION OF THERAPY:

A. ALL INDICATIONS:

1. Adherence to therapy at least 85% of the time as verified by the prescriber or member medication fill history OR adherence less than 85% of the time due to the need for surgery or treatment of an infection, causing temporary discontinuation (documentation required)
   AND
2. Documentation of no intolerable adverse effects or drug toxicity
   AND
3. Documentation of positive clinical response as demonstrated by low disease activity and/or improvements in the condition's signs and symptoms. AND
4. (a) Prescriber attests member has had a negative TB screening or TB test result within the last 12 months for initial and continuation of therapy requests
   OR
   (b) For members who have a positive test for latent TB, provider documents member has completed a treatment course (a negative chest x-ray is also required every 12 months) OR that member has been cleared by an infectious disease specialist to begin treatment

DURATION OF APPROVAL:

Initial authorization: 6 months, Continuation of therapy: 12 months

PRESCRIBER REQUIREMENTS:

CROHNS DISEASE/ULCERATIVE COLITIS: Prescribed by or in consultation with a board-certified gastroenterologist, colorectal surgeon or specialist who is consulting with a board-certified gastroenterologist or colorectal surgeon

PSORIATIC ARTHRITIS (PsA): Prescribed by or in consultation with a board-certified rheumatologist or dermatologist

CHRONIC PLAQUE PSORIASIS: Prescribed by or in consultation with a board-certified dermatologist
[If prescribed in consultation, consultation notes must be submitted within initial request and reauthorization requests]

AGE RESTRICTIONS:

Plaque Psoriasis: 6 years and older, All other indications: 18 Years of age or older

QUANTITY:

Plaque Psoriasis in adults: ≤100kg= 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks, >100kg= 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks
Plaque Psoriasis adolescents (6 years of age through 17 years of age) = Weight based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter; < 60kg= 0.75mg/kg, 60kg-100kg = 45mg, > 100kg= 90 mg
Psoriatic Arthritis in adults: 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks
Psoriatic Arthritis with moderate-to-severe Psoriasis in adults >100 kg: 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks
Crohn's Disease and Ulcerative Colitis Initial adult IV dosage: <55kg= 260 mg (2 vials), 55-85kg= 390mg (3 vials), > 85kg= 520mg (4 vials) maintenance of remission- 90 mg SC 8 weeks after IV induction, then 90mg every 8 weeks thereafter

When requests for off-label dosing, dose escalation, or dose intensification are received, requests will be reviewed

for evidence that current or standard dosing is not adequate to produce a therapeutic level of drug (eg, pharmacokinetic failure), clinical failure or significant loss of response is present, and the requested dosing is established as safe and effective for the condition. There are certain situations where no additional amount of drug is likely to produce or recapture clinical effect because the condition is no longer responsive to the drug(eg, pharmacodynamic failure) or the drug cannot reach the site of activity at sufficient levels. The following items will assist reviewers in determining if the requested dosing is medically necessary:

- *FDA or compendium-supported dosing and therapeutic monitoring recommendations for the drug*
- *Member claims/adherence history*
- *Clinical documentation of the member's response to current or standard dosing regimens (disease activity indices if commonly used in clinical practice or documentation to approximate them may be necessary to demonstrate the response)*
- *In conjunction with documented clinical failure or loss of response or wearing off of effect, test results that demonstrate failure of current or standard dosing to reach established treatment thresholds (e.g., established therapeutic monitoring recommendations)*
- *If applicable, documentation showing the member does not have conditions which make achieving a therapeutic level of drug unlikely even with dose intensification (e.g., dose intensification may be futile due to the presence of anti-drug antibodies, protein losing enteropathy, nephrotic syndrome, severe drug excretion or malabsorption issues, etc.)*
- *In certain situations, documentation, or peer-to-peer determination that re-induction cannot be tried to recapture response as an alternative to long term dose escalation or intensification*

PLACE OF ADMINISTRATION:

The recommendation is that infused medications in this policy will be for pharmacy or medical benefit coverage administered in a place of service that is a non-hospital facility-based location as per the MolinaHealth Care Site of Care program.

The recommendation is that injectable medications in this policy will be for pharmacy or medical benefit coverage and the subcutaneous injectable products administered in a place of service that is a non-hospital facility-based location as per the Molina Health Care Site of Care program.

Note: Site of Care Utilization Management Policy applies for Stelara (ustekinumab). For information on site of care, see
Specialty Medication Administration Site of Care Coverage Criteria (molinamarketplace.com)

DRUG INFORMATION

ROUTE OF ADMINISTRATION:

Subcutaneous, Intravenous

DRUG CLASS:

Interleukin Antagonists

FDA-APPROVED USES:

Indicated for the treatment of:
Adult patients with:

- moderate to severe plaque psoriasis (Ps) who are candidates for phototherapy or systemic therapy.
- active psoriatic arthritis (PsA), alone or in combination with methotrexate
- moderately to severely active Crohn's disease (CD).
- moderately to severely active ulcerative colitis.

Pediatric patients 6 years and older with:

- moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy**.**

COMPENDIAL APPROVED OFF-LABELED USES:
None

APPENDIX

APPENDIX:
None

BACKGROUND AND OTHER CONSIDERATIONS

BACKGROUND:
Stelara is indicated for the treatment of those ≥ 12 years of age with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, for adult patients ≥ 18 years of age with active psoriatic arthritis (PsA) alone or in combination with methotrexate (MTX), and for moderate to severe active Crohn's Disease, in patients who have failed or were intolerant to immunomodulators or corticosteroids, but never failed a tumor necrosis factor inhibitor (TNFi), or in patients who failed or were intolerant to at least on TNFi. Stelara is a human immunoglobulin G (IgG) 1κ monoclonal antibody against the p40 subunit of the interleukin (IL)-12 and IL-23 cytokines,
which are involved in inflammatory and immune responses. It is administered by subcutaneous (SC) injection under the supervision of a physician, although with proper training patients may self-inject. Stelara for intravenous IV infusion is indicated for the treatment of adults ≥ 18 years of age with moderate to severe active Crohn's disease, in patients who have failed or were intolerant to immunomodulators or corticosteroids, but never failed a tumor necrosis factor inhibitor (TNFi), or in

patients who failed or were intolerant to at least one TNFi. It is a human immunoglobulin G (IgG) 1κ monoclonal antibody against the p40 subunit of the interleukin (IL)-12 and IL-23 cytokines, which are involved in inflammatory and immune responses. In Crohn's disease, a single weight-based dose is administered by IV infusion. Following induction therapy with the IV product, the recommended maintenance is Stelara for subcutaneous (SC) injection, given as a 90 mg SC injection administered8weeks after the initial IV dose, then once every 8 weeks (Q8W) thereafter

CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:
All other uses of Stelara (ustekinumab) that are not an FDA-approved indication or not included in the 'Coverage Criteria' section of this policy are considered not medically necessary. This is subject to change based on research and medical literature, or at the discretion of Molina Healthcare.

OTHER SPECIAL CONSIDERATIONS:
None

CODING/BILLING INFORMATION

Note: 1) This list of codes may not be all-inclusive. 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement

HCPCS CODE	DESCRIPTION
J3357	Ustekinumab, for subcutaneous injection, 1mg
J3358	Ustekinumab, for intravenous injection, 1mg

AVAILABLE DOSAGE FORMS:
Subcutaneous Injection: 45 mg/0.5 mL or 90 mg/mL in a single-dose prefilled syringe OR 45 mg/0.5 mL in a single-dose vial
Intravenous Infusion: 130 mg/26 mL (5 mg/mL) solution in a single-dose vial

REFERENCES

1. Stelara® injection [prescribing information]. Horsham, PA: Janssen Biotech, Inc. December 2020.
2. Leonardi C, Kimball AB, Papp KA, et al, for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with psoriasis: 76-weeks results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665- 1674.
3. Papp KA, Langley RG, Lebwohl M, et al, for the PHOENIX 2 study investigators. Efficacy andsafety of ustekinumab, a human interleukin12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-1684.
4. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management ofplaquepsoriasis. Arch Dermatol. 2012;148(1):95-102.
5. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre,double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780-789.
6. Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents forthe treatment of rheumatic diseases, 2012. Ann Rheum Dis. 2013;72 Suppl 2:ii2-34.
7. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008;135:1130-1141.
8. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapyin refractory Crohn's disease. N Engl J Med. 2012;367(16):1519-1528.
9. Segal BM, Constantinescu CS, Raychauhuri A, et al, on behalf of the ustekinumab MS investigators. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab,in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008;7:796-804.
10. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4-12.
11. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriaticarthritis. Ann Rheum Dis. 2009;68(9):1387-1394.
12. Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-conceptstudy (TOPAS). Ann Rheum Dis. 2014;73(5):817-823. • Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease - the McGill experience. J Crohns Colitis. 2014;8(11):1516-2152.